Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

1. Nivolumab (Opdivo) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)

Nivolumab (Opdivo) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC) Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC) - Repository of AIHTA GmbH English | Browse - - - Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC) Grössmann (...) , N. (2020): Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Oncology Fact Sheet Nr. 26. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 79kB Item Type: Oncology Fact Sheet Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 26 Deposited on: 18 Nov 2020 11:48 Last Modified: 18 Nov 2020 11:48 Repository Staff Only: © Copyright ,

2021 Austrian Institute of Health Technology Assessment

2. Nivolumab (Opdivo) plus ipilimumab (Yervoy) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)

Nivolumab (Opdivo) plus ipilimumab (Yervoy) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) - Repository of AIHTA GmbH English | Browse - - - Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) Grössmann, N. (2020): Nivolumab (Opdivo®

2021 Austrian Institute of Health Technology Assessment

3. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Full Text available with Trip Pro

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Jan 15;JCO2001605. doi: 10.1200/JCO.20.01605. Online ahead of print. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus

2021 EvidenceUpdates

4. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma Full Text available with Trip Pro

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: Get (...) at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 Nov 20;38(33):3937-3946. doi: 10.1200/JCO.20.00995. Epub 2020 Sep 30. Five-Year Outcomes With Nivolumab in Patients With Wild-Type

2020 EvidenceUpdates

5. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153 Full Text available with Trip Pro

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153 Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) of print. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153 , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 The US Oncology Network/Oncology Hematology Care, Cincinnati, OH. 2 David Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network, Los Angeles, CA. 3 West Cancer Center, Memphis, TN. 4 Sarah Cannon Research Institute/Florida Cancer Specialists, Cape Coral, FL. 5 Sarah

2020 EvidenceUpdates

6. Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy

Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy T echnology appraisal guidance Published: 21 October 2020 www.nice.org.uk/guidance/ta655 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 18Contents Contents 1 Recommendations 4 2 Information about nivolumab 6

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

7. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) Share Permalink Copy Page navigation Lancet Oncol Actions . 2020 Nov;21(11):1465-1477. doi: 10.1016/S1470-2045(20)30494-0. Epub 2020 Sep 19. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy. Electronic address

2020 EvidenceUpdates

8. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 Jun 1;38(16):1814-1823. doi: 10.1200/JCO.19.02059. Epub 2020 Apr 10. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York

2020 EvidenceUpdates

9. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. (Abstract)

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Nivolumab and ipilimumab, alone or in combination, are widely used immunotherapeutic treatment options for patients with advanced-ie, unresectable or metastatic-melanoma. This criterion, however, excludes patients with stage IV melanoma with no evidence of disease. We therefore (...) aimed to evaluate the safety and efficacy of adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus a placebo in this patient population.We did a randomised, double-blind, placebo-controlled, phase 2 trial in 20 German academic medical centres. Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy. Key exclusion criteria included uveal or mucosal melanoma, previous therapy with checkpoint inhibitors, and any previous

2020 Lancet

10. A Comparison of nivolumab and pembrolizumab for advanced NSCLC in the second-line treatment: A Systematic Review and Network Meta-analysis Full Text available with Trip Pro

A Comparison of nivolumab and pembrolizumab for advanced NSCLC in the second-line treatment: A Systematic Review and Network Meta-analysis A Comparison of nivolumab and pembrolizumab for advanced NSCLC in the second-line treatment: A Systematic Review and Network Meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting (...) preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research A Comparison of nivolumab and pembrolizumab for advanced NSCLC in the second-line treatment: A Systematic Review and Network Meta-analysis jie zhang, rui zhou, jing zhu jie zhang Chongqing Medical University First Affiliated Hospital rui zhou Chongqing Medical University First Affiliated

2020 Research Square

11. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis Full Text available with Trip Pro

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints (...) . The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis Lihu Gu, Shengnan Li, Nannan Du, Qigu Yao, Xiaojun Fu, Yuanmei Lou, Mengru Wang, Feiyan Mao, Danyi Mao, Parikshit Asutosh Khadaroo, Yingying Tang Lihu Gu Ningbo No 2

2020 Research Square

12. Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12

Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12 1 Translation of addendum A19-54 Nivolumab (Nierenzellkarzinom) – Addendum zu den Aufträgen A19-11 und A19-12 (Version 1.0; Status: 19 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 19 July 2019 1.0 Commission: A19-54 Version: Status: IQWiG Reports – Commission (...) No. A19-54 Nivolumab (renal cell carcinoma) – Addendum to Commissions A19-11 and A19-12 1 Addendum A19-54 Version 1.0 Nivolumab – Addendum to Commissions A19-11 and A19-12 19 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (renal cell carcinoma) – Addendum to Commissions A19-11 and A19-12 Commissioning agency: Federal Joint Committee Commission awarded on: 24 June 2019

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

13. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. Full Text available with Trip Pro

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC.In this open-label, phase 3 trial, we randomly assigned (...) patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus

2019 NEJM

14. Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation

Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can (...) at any time. Hide Search Register by 26 November to vote in the General Election on 12 December. Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation Patients on nivolumab who present with diarrhoea or other symptoms of colitis, and those who do not respond to steroid treatment for immune-related colitis, should be investigated to exclude other causes, including infections such as cytomegalovirus (CMV). Published 18 October 2019 From: Therapeutic area

2019 MHRA Drug Safety Update

15. Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (Nierenzellkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 May 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-11 Nivolumab (...) (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-11 Version 1.0 Nivolumab (renal cell carcinoma) 13 May 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 4 February

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Full Text available with Trip Pro

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial.We randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg (...) per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group.At a minimum follow-up of 60 months

2019 NEJM

17. Ipilimumab/nivolumab (Yervoy/Opdivo) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma

Ipilimumab/nivolumab (Yervoy/Opdivo) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma Ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma | Report | National Health Care Institute You are here: Ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma Search within (...) English part of National Health Care Institute Search Ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma Zorginstituut Nederland has completed its assessment whether ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma, can be included in the insured package. Due to its expected high costs the Minister of Health, Welfare

2019 National Health Care Institute (Zorginstituut Nederland)

18. Nivolumab (Opdivo) - for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC)

Nivolumab (Opdivo) - for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC) 1 Published 10 June 2019 1 SMC2153 nivolumab 10mg/ml concentrate for solution for dilution (Opdivo®) Bristol-Myers Squibb Pharmaceuticals Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission assessed under the end of life process nivolumab (Opdivo ® ) is accepted for use within NHSScotland. Indication under review: in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC). Overall survival was significantly longer in the nivolumab plus ipilimumab group compared with a multiple receptor tyrosine kinase inhibitor in a phase III study in treatment naïve patients

2019 Scottish Medicines Consortium

19. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma Niv Nivolumab with ipilimumab for untreated olumab with ipilimumab for untreated advanced renal cell carcinoma advanced renal cell carcinoma T echnology appraisal guidance Published: 15 May 2019 www.nice.org.uk/guidance/ta581 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 24Contents Contents 1

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

20. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial Full Text available with Trip Pro

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma. We aimed to assess whether health-related quality of life (HRQoL) could be used to further describe (...) the benefit-risk profile of nivolumab plus ipilimumab versus sunitinib.In the phase 3, randomised, controlled, CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced or metastatic renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by risk status into favourable, intermediate, and poor risk subgroups and randomly assigned (1:1) to open-label nivolumab 3 mg/kg plus ipilimumab 1 mg

2019 EvidenceUpdates